NEWS AND RESOURCES

PRESS

Press

April 15, 2026

Elion Therapeutics

Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection

June 17, 2024

Elion Therapeutics

Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund

December 5, 2023

NIH Research Matters

Designing a safer antifungal drug by Sharon Reynolds

November 8, 2023

Nature Podcast

How to tame a toxic yet life-saving antifungal” by Benjamin Thompson & Nick Petrić Howe with Dr Martin Burke

More press

Presentations

Turletricin (EL219/SF001) a novel, once-weekly, non-nephrotoxic polyene antifungal takes a novel clinical trial approach.

Maertens J and Marr K. Presented at ESCMID Global. April 18, 2026; Munich, Germany.
Thanks to the ESCMID technical team for the recording.

Turletricin (EL219), a long-acting, non-nephrotoxic polyene antifungal.

Sandison T, et al. Presented at IMARI. January 28-30, 2026; Las Vegas, NV.

Turletricin (EL219), a long-acting, non-nephrotoxic polyene antifungal.

Sandison T. Presented at IMARI. January 28-30, 2026; Las Vegas, NV.

In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024.

Arends SJR, et al. Presented at IDWeek. October 19-22, 2025; Atlanta, GA.

More presentations

Publications

The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused by Coccidioides immitis

Wiederhold, et al. Antimicrobial Agents and Chemotherapy. 2026.

Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates

Youssef, et al. Antimicrobial Agents and Chemotherapy. 2026.

In vitro activity of SF001: a next-generation polyene versus amphotericin B

Vahedi-Shahandashti and Lass-Flörl. Antimicrobial Agents and Chemotherapy. 2025.

Efficacy assessments of EL219, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam, et al. Antimicrobial Agents and Chemotherapy. 2025.

In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model

Lepak, et al. Antimicrobial Agents and Chemotherapy. 2024.

Tuning sterol extraction kinetics yields a renal sparing polyene antifungal.

Maji, et al. Nature. 2023.

More publications